Direct compression of (2S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-pyrrolidinecarboxylic acid phenylmethyl ester avoids aqueous binder systems in the preparation of an immediate-release oral tablet and preserves the benzyl ester function during manufacturing. Before compression, the active is released according to 21 CFR 211.84, with identity by infrared absorption, assay and related substances by reversed-phase high-performance liquid chromatography, residual solvents by headspace gas chromatography under ICH Q3C, and elemental impurities by inductively coupled plasma mass spectrometry under ICH Q3D. The API is delumped through a conical screen fitted with a 500 µm round-hole screen; if the retained fraction on a 250 µm sieve exceeds 0.5% w/w, a pin mill is operated at 6,000 rpm to reduce agglomerates. The direct-compression matrix places the active at 6.0 wt% to 14.0 wt%, microcrystalline cellulose PH102 at 48.0 wt% to 56.0 wt%, lactose monohydrate at 24.0 wt% to 32.0 wt%, croscarmellose sodium at 2.0 wt% to 3.0 wt%, colloidal silicon dioxide at 0.5 wt% to 1.0 wt%, and magnesium stearate at 0.5 wt% to 1.0 wt%. Blending is performed in a 300 L bin blender at 12 rpm for 18 min, followed by lubrication for 3 min. Compression on a 27-station rotary press uses 8.0 mm flat-faced bevel-edged tooling, pre-compression force 1.5 kN to 2.5 kN, main compression force 6.0 kN to 12.0 kN, and turret speed 25 rpm to 35 rpm. Weight uniformity is controlled by USP <905> with an acceptance value not larger than 15.0; hardness is measured with a linear-drive hardness tester in the range of 70 N to 110 N, and friability per USP <1216> is not more than 1.0% after 100 revolutions. Disintegration per USP <701> is completed in 900 mL of 0.01 N hydrochloric acid at 37°C ± 0.5°C within 30 min; dissolution per USP <711> Apparatus II at 50 rpm releases not less than 80% of the labeled amount at 60 min. The terminal product is an immediate-release oral tablet.

What Limits Moisture Exposure in Aqueous Wet Granulation of the Phenylmethyl Ester Prodrug?

Wet granulation of the active into a granule intermediate is viable only when the aqueous binder level is strictly limited because the phenylmethyl ester is prone to hydrolysis in the presence of free water. Binder solution of hypromellose 2910 at 3.0% w/w in purified water is sprayed at 10–14% w/w of dry powder mass into a 600 L top-drive high-shear granulator equipped with an impeller speed of 110 rpm to 130 rpm and a chopper speed of 1,500 rpm. Granule endpoint is determined by an impeller torque rise of 2.0 N·m to 3.0 N·m above the dry-mix baseline; exceeding this window produces dense granules and increases localized moisture retention. The wet mass is dried in a fluid-bed dryer at an inlet air temperature of 50°C to 55°C with product temperature not above 38°C; loss on drying per USP <731> is brought to 1.0% w/w to 1.8% w/w. The dried granules are milled through a 1.25 mm oscillating screen; the fraction retained above 1.00 mm is limited to not more than 15%. A representative granule formulation for single-dose sachets contains the active at 5.0 wt% to 10.0 wt%, lactose monohydrate at 55.0 wt% to 65.0 wt%, microcrystalline cellulose at 15.0 wt% to 20.0 wt%, sodium starch glycolate at 2.0 wt% to 3.0 wt%, hypromellose 2910 at 2.5 wt% to 3.0 wt%, and magnesium stearate at 0.5 wt% to 0.8 wt%. Storage of the finished sachets at 40°C / 75% RH according to ICH Q1A(R2) is used to monitor ester hydrolysis; published kinetic data for this exact brominated imidazopyrazine ester in sachet form is limited, and therefore a moisture specification below 2.0% w/w after packaging is considered a critical control point. The terminal granule intermediate is filled into single-dose sachets at a target fill weight of 1,000 mg ± 5% or compressed into tablets after final lubrication.

Hard Capsule Filling Where Low-Dose Content Uniformity and Hydrolysis Control Intersect

Low-dose capsule filling of the phenylmethyl ester derivative depends on geometric pre-dispersion to maintain content uniformity under USP <905> when the active is present at 2.0 wt% to 5.0 wt% of the final filled mass. The API is first triturated with lactose monohydrate at a 1:5 ratio by weight and passed through a 600 µm screen; the premix is then added to a 200 L V-blender and mixed with microcrystalline cellulose PH102 and croscarmellose sodium. Final lubrication uses magnesium stearate at 0.5 wt% to 0.75 wt%, screened through a 1.0 mm sieve and blended for 3 min at 15 rpm. Capsule filling on a dosator-type machine uses size 3 hard gelatin capsules and a target net fill weight of 180 mg; in-process weight checks are taken at least every 15 min, and capsules are sorted through a weight sorter to reject units outside ±5% of target. Weight variation is controlled by USP <905> with an acceptance value not greater than 15.0. Dissolution is tested per USP <711> Apparatus I at 100 rpm in 900 mL of 0.1 N hydrochloric acid at 37°C ± 0.5°C; not less than 80% of the labeled active is released at 45 min. Residual moisture of the blend and capsule shell system is controlled below 1.0% w/w by Karl Fischer titration according to USP <921>; free water originating from the gelatin shell can migrate into the powder blend and accelerate ester hydrolysis. Stability evaluation follows ICH Q1A(R2) at 40°C / 75% RH and 25°C / 60% RH. The terminal product is an immediate-release hard capsule for oral administration.

Lyophilized injectable formation of (2S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-pyrrolidinecarboxylic acid phenylmethyl ester is carried out as an aseptic process after sterile filtration. The compounding area meets ISO 14644-1 class 7, and the filling line operates under class 5 unidirectional airflow. The formulation solution contains the active at 2.0 mg/mL to 5.0 mg/mL in 10 mM citrate buffer adjusted to pH 5.0 ± 0.2; mannitol is added at 4.0% w/v as a cryoprotectant, and sodium chloride is omitted to avoid precipitation of the ester in the frozen matrix. The compounded solution is held at 2–8°C for not more than 8 h from dissolution to sterile filtration to limit aqueous hydrolysis. Sterile filtration is performed through a 0.22 µm polyvinylidene difluoride membrane; the solution is filled into 10 mL USP Type I borosilicate glass vials at 5.2 mL per vial. Lyophilization uses shelf pre-cooling to -45°C, primary drying at -20°C for 36 h with a chamber pressure of 80 mTorr, and secondary drying at 30°C for 6 h; cake moisture is controlled to not more than 1.0% w/w by Karl Fischer titrimetry. The finished cake is tested for reconstitution time, visible particulates per USP <790>, subvisible particulates per USP <788> with limits of 6,000 particles per vial at ≥ 10 µm and 600 particles per vial at ≥ 25 µm, sterility per USP <71>, and bacterial endotoxins per USP <85> with a limit of not more than 0.5 EU/mg. The terminal product is a lyophilized powder for reconstitution with Sterile Water for Injection or 0.9% sodium chloride injection before intravenous administration.

When Terminal Sterilization Is Considered for the Injectable Intermediate

Terminal moist-heat sterilization at 121°C for 15 min is not accepted for this phenylmethyl ester derivative because forced degradation screening in citrate buffer at pH 5.0 demonstrates hydrolysis of the ester function under autoclave conditions; therefore, aseptic processing is selected according to 21 CFR 210.211, 21 CFR 211.113, and EU GMP Annex 1. Bulk solution is held at 2–8°C for no more than 8 h before sterile filtration; filling line temperature is maintained at 22°C ± 2°C. The sterilizing-grade filter has a pore size of 0.22 µm and is integrity tested by bubble point or diffusive flow before and after use. Equipment and process qualification follows ASTM E2500; environmental monitoring for viable and non-viable particles is conducted in the aseptic filling zone. Container–closure integrity is verified by dye ingress or vacuum decay according to USP <1207>; the closure is a 20 mm bromobutyl rubber stopper with an ethylene tetrafluoroethylene coating. Extractables and leachables screening is performed by headspace gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry because the brominated imidazopyrazine ring and phenylmethyl ester may interact with stopper additives. Elemental impurities are controlled according to ICH Q3D with parenteral permitted daily exposure limits applied to palladium and chromium. Published stability data for this exact ester under autoclave stress is limited; the exclusion of terminal sterilization is therefore based on comparative hydrolysis of the benzyl ester function in model aqueous buffers rather than on a commercial registration dataset. The finished injectable product is stored at 2–8°C protected from light; freeze–thaw cycling and thermal cycling of the lyophilized cake are used to confirm that residual moisture above 1.0% w/w does not produce solid-state hydrolysis in the container.

Oral Suspension and Enteric-Coated Granule Architectures for pH-Sensitive Ester Prodrugs

An oral suspension prepared from the active as a microcrystalline dispersion is used when dose flexibility is required; the API is wet-milled in a planetary ball mill with 0.6 mm zirconia beads to a d90 below 30 µm and a d50 between 5 µm and 15 µm. The suspending vehicle contains microcrystalline cellulose and carboxymethylcellulose sodium at 0.45% w/v, sodium citrate dihydrate at 0.25% w/v, citric acid monohydrate to pH 5.0 ± 0.2, methylparaben at 0.15% w/v, propylparaben at 0.05% w/v, and sorbitol solution at 20.0% w/v; the active is incorporated at 10 mg/mL to 20 mg/mL. The suspension is filled into amber 100 mL glass bottles and stored at 2–8°C; viscosity is measured with a rotational viscometer using spindle #2 at 60 rpm, with a target range of 150 mPa·s to 350 mPa·s. For enteric-coated granule architectures, the active is layered onto microcrystalline cellulose spheres in a rotor granulator, then coated with a primary seal coat of hypromellose 2910 and a second coat of methacrylic acid copolymer type A/B; coating is performed in a fluid-bed bottom-spray coater at an inlet air temperature of 45°C to 50°C, atomizing air pressure 1.2 bar, and spray rate 8 g/min to 12 g/min. The enteric-coated granules are tested by the two-stage dissolution procedure of USP <711>, with not more than 10% released after 2 h in 0.1 N hydrochloric acid followed by not less than 80% released within 45 min in pH 6.8 phosphate buffer. The finished granule product is either filled into hard capsules or single-dose sachets; the enteric coating limits contact of the phenylmethyl ester with gastric acid and shifts release to the proximal small intestine, where the formulation pH modifier can control free water and reduce ester hydrolysis.